Physician profile
William S Suhr
NPI 1265439970
$1,832.36
in general payments reported to CMS, 2019-2025
24 companies · $23.59 in 2025
The $23.59 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,561 · 2020: $132 · 2021: $77.14 · 2022: $38.00 · 2025: $23.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $23.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $23.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $240.91 | 2019-2021 | |
| Pfizer INC. | $217.11 | 2019 | |
| Janssen Pharmaceuticals, INC | $214.15 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $145.73 | 2019 | |
| Amgen INC. | $135.16 | 2019 | |
| Boston Scientific Corporation | $122.07 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $100.20 | 2019-2021 | |
| Ekos Corporation | $93.15 | 2019 | |
| Edwards Lifesciences Corporation | $85.43 | 2019-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Lundbeck LLC | $66.23 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $52.77 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.72 | 2019 | |
| Terumo Medical Corporation | $46.51 | 2019 | |
| Sanofi-Aventis U.S. LLC | $42.73 | 2019 | |
| Amarin Pharma, INC. | $40.76 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $27.74 | 2019-2020 | |
| Medtronic Vascular, INC. | $27.42 | 2019-2020 | |
| Abbott Laboratories | $24.62 | 2022 | |
| Abiomed | $21.13 | 2020 | |
| Alnylam Pharmaceuticals INC. | $20.32 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $18.35 | 2020 | |
| Livanova USA, INC. | $16.83 | 2021 | |
| Novo Nordisk INC | $16.32 | 2020 | |
| Bardy Diagnostics, INC. | $5.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Suhr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.